Cerluten

Descrizione Del Prodotto

1. Classification and Chemical Overview

Cerluten (frequently designated in scientific literature and clinical compendia as peptide complex A-5 or brain peptide bioregulator, with synthetic analogues known as the cytogen peptide Cortexin or related neuro-oligopeptides) belongs to the cytomax class of organ-specific biological response modifiers. Chemically, the natural preparation consists of a purified, low-molecular-weight polypeptide fraction isolated from the cerebral cortex tissue of young mammalian livestock, predominantly bovine donors (Bos taurus). The extraction protocol utilizes gentle acetic acid digestion combined with successive ultrafiltration stages to isolate polypeptide fractions with an upper molecular mass cut-off restricted below $5\text{ to }10\text{ kDa}$. The active fraction comprises ultra-short regulatory oligopeptides spanning 2 to 6 amino acid sequences, trace endogenous nucleopeptides, and tissue-specific neuroregulatory signalling motifs. Synthetic counterparts reproduce targeted sequences chemically—most frequently short di-, tri-, or tetrapeptide motifs (such as Glu-Asp-Arg or related acidic-basic peptide clusters)—using solid-phase peptide synthesis. The formulation is presented in hard gelatin or hydroxypropyl methylcellulose (HPMC) capsules containing standard pharmaceutical excipients such as microcrystalline cellulose, lactose, and calcium stearate.

Within the United Kingdom regulatory framework, Cerluten possesses no marketing authorisation (MA) from the Medicines and Healthcare products Regulatory Agency (MHRA). It is not catalogued in the British National Formulary (BNF) and is not scheduled as a Prescription Only Medicine (POM), Pharmacy (P) medicine, or General Sales List (GSL) drug under the Human Medicines Regulations 2012. Within the UK, this preparation is commercialised strictly as a non-medicinal food supplement or chemical research material governed by the Food Safety Act 1990 and the Nutrition and Health Claims (England) Regulations. In accordance with domestic trading standards and statutory food supplement legislation, commercial distributors are legally prohibited from articulating therapeutic or medicinal claims concerning the prevention, diagnosis, mitigation, or treatment of clinically established neurological or psychiatric pathologies (such as acute ischaemic stroke, traumatic brain injury [TBI], Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, or major depressive disorder).

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of Cerluten is rooted in the tissue-specific epigenetic model of short-chain peptide bioregulation, operating primarily via nuclear transactivation, synaptic homeostasis, and neuroprotection across cortical neuronal and glial networks:

• Epigenetic and Transcriptional Regulation: Due to low molecular mass, compact hydrodynamic volume, and neutral-to-amphiphilic surface charges, the ultra-short oligopeptides in Cerluten cross neuronal and astrocytic plasma membranes. They translocate across the nuclear pore complex into the nucleoplasm, where they bind site-specifically to complementary nucleotide sequences within the major and minor grooves of double-stranded genomic DNA and nucleosomal core histones. This interaction alters nucleosomal packaging, facilitates chromatin unwinding from heterochromatin to open euchromatin, and recruits RNA polymerase II, modulating the transcription of structural and functional genes essential for neuronal differentiation and synaptogenesis.

• Neurotrophic Support and Synaptic Plasticity: In vitro and preclinical models demonstrate that cerebral cortex peptides stimulate the transcriptional expression of essential neurotrophic factors, principally brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and neurotrophin-3 (NT-3). By enhancing neurotrophin signaling cascades via tropomyosin receptor kinase (Trk) receptors, Cerluten supports dendritic arborisation, promotes the expression of postsynaptic density protein 95 (PSD-95) and synaptophysin, and facilitates long-term potentiation (LTP) mechanisms underlying memory encoding and consolidation.

• Neuroprotection and Excitotoxicity Mitigation: In experimental models of cerebral ischaemia and glutamate-induced excitotoxicity, cortical peptides attenuate pathological intracellular calcium ($Ca^{2+}$) overload. They modulate the functional activity of N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunits, reducing excess glutamate accumulation in the synaptic cleft and preserving astrocytic glutamate transporter-1 (GLT-1 / EAAT2) expression.

• Mitochondrial Stability and Apoptosis Resistance: Exposure to cerebral peptide fractions reduces neuronal apoptosis induced by oxidative stress, hypoxia, or toxic protein aggregations (e.g., beta-amyloid fragments). This cytoprotective action is mediated by downregulating pro-apoptotic executioners (caspase-3 and Bax), preserving mitochondrial inner membrane potential ($\Delta\Psi_m$), and transcriptionally upregulating endogenous enzymatic antioxidants, notably superoxide dismutase (SOD) and glutathione peroxidase.

3. Approved UK Clinical Indications and Therapeutic Scope

Cerluten possesses no approved clinical indications in the United Kingdom. No randomized, double-blind, multicentre clinical trials meeting the statutory criteria of the MHRA have been conducted to establish clinical efficacy, therapeutic reproducibility, or neurotoxicological safety profiles.

The National Institute for Health and Care Excellence (NICE) does not endorse, recommend, or integrate Cerluten into any formal clinical pathway. It is entirely absent from clinical guidelines governing stroke and transient ischaemic attack in over 16s (NG128), head injury: assessment and early management (NG232), dementia: assessment, management and support (NG97), and Parkinson’s disease in adults (NG71).

The application of Cerluten is confined strictly to non-clinical consumer wellness contexts and preliminary laboratory research. In exploratory literature and private functional health sectors, it is investigated for:

• Supporting functional physiological resilience of the central nervous system during non-pathological, age-related cognitive decline.

• Complementary nutritional support during convalescence following intense intellectual exertion, mental fatigue, or chronic psychological stress.

• Maintenance of baseline cortical metabolic efficiency and psychomotor speed in ageing populations.

• Preclinical animal models examining cortical microarchitecture preservation, neurovascular coupling, and behavioural adaptation following hypoxic or toxic brain injury.

Cerluten holds no status within the NHS drug tariff, cannot be prescribed on NHS prescription forms (FP10), and must never replace validated clinical treatments, including acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine), NMDA receptor antagonists (memantine), acute thrombolysis (alteplase), antiplatelet secondary prophylaxis (clopidogrel, aspirin), or licensed anticonvulsant and psychotropic regimens.

4. Pharmacokinetic Profile and Metabolic Fate

Because Cerluten is formulated as an oral capsule, its pharmacokinetic disposition is determined by gastrointestinal transport, blood-brain barrier penetration, and physiological peptide clearance kinetics:

• Absorption: Crude protein macromolecules undergo extensive enzymatic cleavage in the stomach by pepsin and in the small intestine by pancreatic endopeptidases (trypsin, chymotrypsin). However, the ultra-short di-, tri-, and tetrapeptides present in Cerluten exhibit structural resistance to complete brush-border aminopeptidase degradation. These intact short peptide sequences cross the apical enterocyte membrane into the portal circulation via the low-affinity, high-capacity proton-coupled peptide transporter 1 (PEPT1). Peak plasma concentrations ($T_{max}$) of intact circulating oligopeptides typically occur within 20 to 50 minutes following oral ingestion.

• Distribution: Following mesenteric absorption and portal transit, the peptides enter the systemic vascular compartment. With a low molecular weight and hydrophilic properties, the apparent volume of distribution ($V_d$) corresponds closely to total extracellular fluid volume. Transport into the central nervous system requires crossing the blood-brain barrier (BBB); small, neutral, and amphiphilic oligopeptides exhibit transient, low-level penetration across brain capillary endothelial cells via passive diffusion, proton-dependent transport, or transcellular transcytosis, reaching cortical parenchymal targets in low nanomolar concentrations. Plasma protein binding is negligible ($<5\%$).

• Biotransformation: Cerluten does not undergo hepatic clearance via the cytochrome P450 (CYP450) microsomal monooxygenase system (e.g., CYP1A2, CYP2D6, CYP3A4). Systemic clearance is mediated entirely by circulating plasma aminopeptidases, carboxypeptidases, and cellular endopeptidases, which rapidly hydrolyse peptide bonds into native constituent individual L-amino acids (such as L-glutamic acid, L-aspartic acid, and L-arginine). These amino acids enter endogenous amino acid turnover and protein synthesis pools.

• Elimination: Systemic elimination of intact peptides is rapid, with an effective half-life ($t_{1/2}$) ranging between 15 and 60 minutes. Direct renal excretion of intact macromolecular peptides is negligible; end-stage metabolites are cleared as urinary urea, with trace carbon atoms exhaled as carbon dioxide via respiratory gas exchange.

5. Physiological Effects and Adverse Event Spectrum

The primary physiological effect documented in preclinical investigations is the normalization of cerebral cortical bioelectrical activity, characterized by stabilized alpha-rhythm index on electroencephalography (EEG), preserved synaptic transmission velocity, and maintenance of neurovascular coupling during metabolic stress. In animal models of experimental neurotrauma and cerebral ischaemia, these agents demonstrate structural maintenance of cortical pyramidal neurons, reduced perifocal vasogenic oedema, and enhanced spatial learning and conditional reflex preservation without inducing pathological cortical hyper-synchrony or seizure activity.

Because Cerluten has not undergone structured, large-scale Phase I–IV clinical pharmacovigilance surveillance, documentation of adverse drug reactions is derived primarily from observational cohorts and preclinical animal toxicology:

• Very Common ($\ge 1/10$): None documented in clinical literature.

• Common ($1/100$ to $<1/10$): Mild, self-limiting gastrointestinal symptoms following oral intake, including transient nausea, epigastric fullness, and mild abdominal discomfort.

• Uncommon ($1/1,000$ to $<1/100$): Transient sensations of mild cephalalgia; mild daytime psychomotor restlessness or initial sleep disturbances (if administered in the late evening); mild, localized cutaneous pruritus or macular rash.

• Rare ($1/10,000$ to $<1/1,000$): Type I immediate allergic hypersensitivity reactions (urticaria, angioedema, or bronchospasm), principally triggered in atopic individuals sensitized to bovine structural protein residues.

• Biological and Diagnostic Hazards: Unregulated preparations derived from non-certified mammalian sources carry theoretical risks of transmissible spongiform encephalopathies (TSE/BSE) if origin verification is absent. Crucially, self-administering unlicensed bioregulators to manage progressive memory loss, focal neurological deficits, acute confusion, or persistent severe headaches presents a critical clinical hazard by potentially delaying diagnostic evaluation for intracranial neoplasms, acute ischaemic stroke, subdural haematoma, normal pressure hydrocephalus, or reversible metabolic encephalopathies.

6. Contraindications, Drug Interactions, and Clinical Precautions

The handling and administration of Cerluten require strict adherence to fundamental neurological, psychiatric, and pharmacological safety parameters:

• Contraindications:

  • Documented hypersensitivity or history of allergic anaphylaxis to bovine-derived biological substances, gelatin, or any formulation excipients.

  • Active central nervous system neoplasms: Absolute contraindication in patients with known or suspected primary brain tumours (e.g., glioblastoma, astrocytoma, meningioma) or cerebral metastases. Modulating transcriptional activity, neurotrophin signalling, or cellular viability pathways in neoplastic intracranial tissue is clinically hazardous.

  • Acute, uncontrolled epilepsy or status epilepticus: Relative contraindication; altering cortical neurochemical balance and synaptic excitability carries unquantified risks in poorly controlled seizure disorders.

  • Pregnancy and lactation: Absolute contraindication due to an absence of embryotoxicity, teratogenicity, and developmental neuro-reproductive safety data, alongside unknown secretion into human breast milk.

  • Paediatric population: Contraindicated in infants, children, and adolescents under 18 years due to an absence of safety and developmental data in the maturing paediatric central nervous system.

• Drug Interactions:

  • Centrally Acting Pharmaceuticals (Anticonvulsants, Antidepressants, Antipsychotics, Sedatives): Concurrent use is not known to involve cytochrome P450 interactions, but theoretical pharmacodynamic alterations in neurotransmitter receptor sensitivity or neurotrophic pathways warrant clinical observation.

  • Nootropics and CNS Stimulants (e.g., piracetam, modafinil, methylphenidate): Concomitant administration may lead to additive central nervous system stimulation, potentially precipitating psychomotor restlessness, anxiety, or insomnia.

  • Anticoagulants and Antiplatelet Agents: Co-administration does not alter standard international normalised ratio (INR) or coagulation cascades, but patients receiving stroke secondary prophylaxis must not modify their antiplatelet or anticoagulant regimens.

  • Cytochrome P450 interactions: There are no documented pharmacokinetic induction or inhibition interactions with hepatic CYP450 isoenzymes.

• Clinical Precautions:

  • Neurological Alarm Symptoms (“Red Flags”): Patients presenting with red flag symptoms—such as sudden-onset facial weakness, arm weakness, or speech disturbance (FAST criteria), acute severe “thunderclap” headache, progressive focal neurological deficits, new-onset seizures in adulthood, unexplained rapid cognitive decline, or persistent papilloedema—mandate immediate emergency hospital admission or urgent specialist neurological referral rather than self-directed supplementation.

  • Neurodegenerative Assessment: Individuals experiencing persistent, progressive memory impairment interfering with activities of daily living require formal clinical evaluation—including cognitive assessment batteries (e.g., MoCA, ACE-III), structural neuroimaging (MRI/CT), and laboratory screens (thyroid function, serum B12/folate)—prior to exploring non-medicinal products.

  • Source Purity: Clinicians and researchers must verify that natural mammalian extracts possess documented batch-specific certification confirming extraction from BSE-free herds and compliance with UK/EU biological safety criteria.

Ulteriori Informazioni